Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells

The heterogeneity of cancer cell signaling is a significant obstacle for the effective development and clinical use of molecularly targeted therapies. As a contribution to a better understanding of the diversity of signaling activities in colorectal cancers (CRCs), we have analyzed the activity of Src family kinases (SFKs), which are implicated in human cancer development, in 64 CRC cell lines. A striking diversity of SFK activity was observed within this panel. Importantly, all CRC lines tested depend on SFK activity for their growth. In addition, SFK activity levels strongly correlated with global levels of tyrosine-phosphorylated (pTyr) proteins in CRC lines. SFK inhibition substantially reduced these pTyr levels, suggesting that SFKs may function as signal integration points and master controllers for the pTyr protein status in CRC lines. The majority of analyzed CRC lines with high-SFK activity express activated c-Met (pYpY1234/1235), a receptor tyrosine kinase contributing to the regulation of cell proliferation, migration, and invasion. Inhibition of SFKs reduced c-Met phosphorylation in most cases, indicating a reversed signal flow from SFK to c-Met. We conclude that SFK activity is important for the growth of CRC lines, although only low activity levels are required. If this also is true for CRC patients, tumors with low-SFK activity may be particularly sensitive to SFK inhibitors, and such patients should be targeted in clinical trials testing SFK inhibitors.

[1]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[2]  H. Kantarjian,et al.  Current and emerging treatment options in chronic myeloid leukemia , 2007, Cancer.

[3]  J. Marshall,et al.  Targeted therapy for colorectal cancer. , 2006, Current opinion in investigational drugs.

[4]  W. Bodmer.  Cancer genetics: colorectal cancer as a model , 2006, Journal of Human Genetics.

[5]  K. Bonham,et al.  Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells , 2006, International journal of cancer.

[6]  Ying Liu,et al.  Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Qiong Shi,et al.  Role of β-arrestin 1 in the metastatic progression of colorectal cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Venook.  Critical evaluation of current treatments in metastatic colorectal cancer. , 2005, The oncologist.

[9]  S. Parsons,et al.  c-Src and cooperating partners in human cancer. , 2004, Cancer cell.

[10]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[11]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[12]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[13]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[14]  D. Coppola,et al.  Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. , 2003, Anticancer research.

[15]  J. Coxhead,et al.  Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[17]  N. Hynes,et al.  Tyrosine kinase signalling in breast cancer , 2000, Breast Cancer Research.

[18]  W. Bodmer,et al.  Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Timothy J. Yeatman,et al.  Activating SRC mutation in a subset of advanced human colon cancers , 1999, Nature Genetics.

[20]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[21]  C. Cartwright,et al.  c-Yes tyrosine kinase activity in human colon carcinoma. , 1993, Oncogene.

[22]  J. Bodmer,et al.  Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Fournel,et al.  Differential regulation of T cell antigen responsiveness by isoforms of the src-related tyrosine protein kinase p59fyn , 1992, The Journal of experimental medicine.

[24]  P. Comoglio,et al.  Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor) , 1991, Molecular and cellular biology.

[25]  J. Ihle,et al.  Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus , 1991, Molecular and cellular biology.

[26]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[27]  E. Sausville,et al.  Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. , 1987, Oncogene research.

[28]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[29]  G. Gallick,et al.  Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. , 2007, Journal of experimental therapeutics & oncology.

[30]  Qiong Shi,et al.  Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Martin.  The hunting of the Src , 2001, Nature Reviews Molecular Cell Biology.

[32]  W. Bodmer.  The Somatic Evolution of Cancer , 1997, Journal of the Royal College of Physicians of London.